Patents by Inventor Hervé Geneste

Hervé Geneste has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210147381
    Abstract: The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 20, 2021
    Inventors: Wilhelm AMBERG, Hervé GENESTE, Wilfried HORNBERGER, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Sean C. TURNER, Jeroen VAN BERGEIJK, Elizabeth VAN DER KAM
  • Publication number: 20200055817
    Abstract: The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Wilhelm AMBERG, Jeroen VAN BERGEIJK, Herve GENESTE, Wilfried HORNBERGER, Elizabeth Louise VAN DER KAM, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Patrick WALLESER, Sean C. TURNER
  • Patent number: 10556907
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 11, 2020
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • Patent number: 10308610
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 4, 2019
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Publication number: 20190135777
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Hervé GENESTE, Andreas HAUPT, Frauke POHLKI, Ana Lucia RELO, Liliane UNGER, Karsten WICKE
  • Patent number: 10280159
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 7, 2019
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Patent number: 10160744
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: December 25, 2018
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Andreas Haupt, Frauke Pohlki, Ana Lucia Relo, Liliane Unger, Karsten Wicke
  • Publication number: 20180222905
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • Publication number: 20180099936
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Patent number: 9938269
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: April 10, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • Publication number: 20180030033
    Abstract: The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: February 1, 2018
    Inventors: Hervé GENESTE, Sean Colm TURNER, Michael OCHSE, Karla DRESCHER, Lawrence A. BLACK, Katja JANTOS
  • Patent number: 9862704
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 9, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Wilfried Hornberger, Charles W. Hutchins, Katja Jantos, Andreas Kling, Loic Laplanche, Marcel Van Gaalen
  • Patent number: 9856220
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 2, 2018
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Patent number: 9840495
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 12, 2017
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Wilfried Hornberger, Charles W. Hutchins, Katja Jantos, Andreas Kling, Loic Laplanche, Marcel Van Gaalen
  • Patent number: 9790203
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 17, 2017
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Sean Colm Turner, Michael Ochse, Karla Drescher, Lawrence A. Black, Katja Jantos
  • Publication number: 20170260158
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 14, 2017
    Inventors: Hervé GENESTE, Andreas HAUPT, Frauke POHLKI, Ana Lucia RELO, Liliane UNGER, Karsten WICKE
  • Patent number: 9688678
    Abstract: The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—; X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims. The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: June 27, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel Van Gaalen
  • Publication number: 20170174672
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 22, 2017
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Patent number: 9657002
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 23, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Katja Jantos, Wilfred Braje, Herve Geneste, Andreas Kling, Liliane Unger, Berthold Behl, Marcel van Gaalen, Wilfried Hornberger, Loic Laplanche, Silke Weber
  • Patent number: 9657034
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 23, 2017
    Assignees: AbbVie Deuschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black, Katja Jantos